Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Home About Us Product Pipeline News Investors Contacts Careers

About Us

Overview Management Team Board of Directors Governance


Management Team


Erin E. Jones
Vice President, Global Regulatory Affairs, Medical Writing, and Pharmacology/Toxicology


Mr. Jones joined Puma as our Vice President, Global Regulatory Affairs in 2014. Prior to joining Puma, Mr. Jones worked at BioMarin Pharmaceutical Inc. between 2012 and 2014, with Regulatory oversight of the PKU, gene therapy, and oncology programs.

While working at Genentech from 2006 to 2012, he held a variety of positions including North America Oncology Team Leader, HER Franchise Group Leader, and Head of Regulatory Intelligence. In his roles at Genentech, Mr. Jones oversaw the HER mechanism franchise, where he led and oversaw Regulatory aspects of late-stage development and BLA submissions for Kadcyla™ and Perjeta™ in HER2-positive metastatic breast cancer, and obtained approvals for Herceptin™ in HER2-positive adjuvant breast and metastatic gastric cancers.

Previously, he worked at Cephalon Inc. on strategies that led to the approval for Treanda™ in NHL and CLL, and at Centocor Inc. in increasing levels of responsibility in the areas of Discovery Research, Clinical Pharmacology, Clinical, and Regulatory.

Mr. Jones received a B.S. from the University of Pittsburgh in 1994, and an M.S. from Pennsylvania State University in 2001.

Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax